03/20/2017
San Francisco, CA, March 20, 2017 —  Parthenon Capital Partners (“Parthenon”) and M2 Group Holdings, LLC (“M2”) have announced a strategic partnership with John Moody, Co-founder and former President of Matrix Financial Solutions (“Matrix”), to build the next generation Financial Technology platform for retirement plan, bank trust and wealth management providers through a combination of strategic acquisitions and organic growth. Mr. Moody has more than 30 years of financial services experience and through his leadership built Matrix into one of the leading Custodian and mutual fund trading providers in the industry. In 2011, Matrix was sold to Broadridge Financial Solutions (NYSE: BR), under whose ownership Mr. Moody was able to acquire the Wilmington Trust retirement business from M&T Bank in 2015 and nearly triple the assets under administration before exiting the business earlier this year. “This partnership complements Parthenon’s longstanding industry effort in asset management technology,” said Brian Golson, Managing Partner and Co-CEO of Parthenon Capital. “After 10 years of looking for ways to work together, we’re pleased to have the opportunity to collaborate with John. He’s a talented and experienced leader with an outstanding vision for the sector.”
Mr. Moody commented, “the opportunity to continue to drive innovation in technology enabled administration has never been better given the changing regulatory framework. Moreover, we are pursuing this opportunity at a time of critical importance for Americans to invest and save in smarter and more cost efficient ways.”
Parthenon is joined by M2, a newly formed operating company focused on financial services. The principals of M2 and Parthenon have worked together for more than 10 years. About John Moody
John Moody was most recently president of Matrix Financial Solutions, a business he founded, built and sold to Broadridge Financial Solutions. Mr. Moody previously served on the boards of CiKR (Council of Independent 401(k) Recordkeepers) and SPARK (Society of Pension Administrators and Record Keepers) helping to shape the retirement industry’s key initiatives. Mr. Moody is a pioneer in the “open architecture” movement that is now sweeping the 401(k) industry. Seeing the need for more flexibility and an early adaptor of fee disclosure, Moody’s vision made Matrix a favorite among independent TPAs/Record Keepers and major wirehouses and broker/dealer firms looking to get ahead of the regulatory push. Mr. Moody received a B.B.A. in Economics from the University of Iowa. About Parthenon Capital Partners
Parthenon Capital Partners (www.parthenoncapitalpartners.com) is a leading mid-market private equity firm based in Boston and San Francisco. Parthenon utilizes niche industry expertise and a deep execution team to invest in growth companies in service industries. Parthenon seeks to be an active and aligned partner to management, either through recapitalization transactions or by backing new executives. Parthenon has particular expertise in financial and insurance services, healthcare technology and services, and business services, but seeks any service, technology or delivery business with a strong value proposition and proprietary know-how. Parthenon’s investment team has deep experience in corporate strategy, human capital, capital markets, and operations, thereby enabling the firm to pursue complex, multi-faceted value creation opportunities. About M2
M2 Group Holdings is an operating company that makes significant long term investments in entrepreneurs within the financial services sector. M2 combines a thesis based approach with patient capital to accelerate the business models of those financial services companies best positioned to take advantage of the continual shifts within the financial services sector. M2’s differentiated experience in the financial services sector as leading advisors, principals, and operators allow us to drive our partner companies to achieve unprecedented growth.

Parthenon Capital Partners and M2 Group Holdings Announces Strategic Partnership with John Moody

Parthenon and M2 team up with Matrix ex-president to build fintech platform
March 21, 2017
By Iris Dorbian
Parthenon Capital Partners, a mid-market private equity firm and M2, a financial services-focused company have teamed up with John Moody, co-founder and ex-president of Matrix Financial Solutions, to build a next-generation financial tech platform for retirement plan, bank trust and wealth management providers. No financial terms were disclosed. PRESS RELEASE
SAN FRANCISCO–(BUSINESS WIRE)–Parthenon Capital Partners (“Parthenon”) and M2 Group Holdings, LLC (“M2”) have announced a strategic partnership with John Moody, Co-founder and former President of Matrix Financial Solutions (“Matrix”), to build the next generation Financial Technology platform for retirement plan, bank trust and wealth management providers through a combination of strategic acquisitions and organic growth. Mr. Moody has more than 30 years of financial services experience and through his leadership built Matrix into one of the leading Custodian and mutual fund trading providers in the industry. In 2011, Matrix was sold to Broadridge Financial Solutions (NYSE: BR), under whose ownership Mr. Moody was able to acquire the Wilmington Trust retirement business from M&T Bank in 2015 and nearly triple the assets under administration before exiting the business earlier this year. “This partnership complements Parthenon’s longstanding industry effort in asset management technology,” said Brian Golson, Managing Partner and Co-CEO of Parthenon Capital. “After 10 years of looking for ways to work together, we’re pleased to have the opportunity to collaborate with John. He’s a talented and experienced leader with an outstanding vision for the sector.”
Mr. Moody commented, “the opportunity to continue to drive innovation in technology enabled administration has never been better given the changing regulatory framework. Moreover, we are pursuing this opportunity at a time of critical importance for Americans to invest and save in smarter and more cost efficient ways.”
Parthenon is joined by M2, a newly formed operating company focused on financial services. The principals of M2 and Parthenon have worked together for more than 10 years. About John Moody
John Moody was most recently president of Matrix Financial Solutions, a business he founded, built and sold to Broadridge Financial Solutions. Mr. Moody previously served on the boards of CiKR (Council of Independent 401(k) Recordkeepers) and SPARK (Society of Pension Administrators and Record Keepers) helping to shape the retirement industry’s key initiatives. Mr. Moody is a pioneer in the “open architecture” movement that is now sweeping the 401(k) industry. Seeing the need for more flexibility and an early adaptor of fee disclosure, Moody’s vision made Matrix a favorite among independent TPAs/Record Keepers and major wirehouses and broker/dealer firms looking to get ahead of the regulatory push. Mr. Moody received a B.B.A. in Economics from the University of Iowa. About Parthenon Capital Partners
Parthenon Capital Partners (www.parthenoncapitalpartners.com) is a leading mid-market private equity firm based in Boston and San Francisco. Parthenon utilizes niche industry expertise and a deep execution team to invest in growth companies in service industries. Parthenon seeks to be an active and aligned partner to management, either through recapitalization transactions or by backing new executives. Parthenon has particular expertise in financial and insurance services, healthcare technology and services, and business services, but seeks any service, technology or delivery business with a strong value proposition and proprietary know-how. Parthenon’s investment team has deep experience in corporate strategy, human capital, capital markets, and operations, thereby enabling the firm to pursue complex, multi-faceted value creation opportunities. About M2
M2 Group Holdings is an operating company that makes significant long term investments in entrepreneurs within the financial services sector. M2 combines a thesis based approach with patient capital to accelerate the business models of those financial services companies best positioned to take advantage of the continual shifts within the financial services sector. M2’s differentiated experience in the financial services sector as leading advisors, principals, and operators allow us to drive our partner companies to achieve unprecedented growth. Get your FREE trial or subscribe now to Buyouts to find new deal opportunities, super-charge your fundraising efforts and track top managers. Sign up to our Newsletter
Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:
First Name:

Parthenon and M2 team up with Matrix ex-president to build fintech platform

The Future Cities Institute works collaboratively with local governments, city infrastructure providers, educational institutes, and industry stakeholders to empower cities and citizens, and unlock their potential by delivering services and smart city solutions that can help them lead healthier lives, enriched by education and powered by digital technologies.

The Future Cities Institute

With this partnership with The Future Cities Institute , M2 can create a new breed of professionals , managers , and leaders capable of addressing the gap between technical and business skills , and business challenges relating to technological advancements , ''

M2 Academy partners The Future Cities Institute to provide globally-recognised smart city

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

M2 Group Holdings is developing a disposable drug delivery system which will initially be used for the treatment of Type I diabetes.

M2 Group Holdings

Thomas McNerney & Partners

Israeli medtech company InMode is strengthing its position in the women’s health market through the acquisition of Viveve Medical ‘s intellectual property assets. Viveve Medical specializes in women’s wellness and more specifically the treatment of female stress urinary incontinence (SUI). With the acquisition, all of Viveve’s worldwide patents have been transferred and registered under InMode. Earlier this year in January 2023 Viveve Medical, back then NASDAQ listed, released topline results from its U.S. Pivotal PURSUIT clinical trial, investigating the use of Viveve treatment for stress urinary incontinence (SUI) in women. Unfortunately, the study did not achieve its primary endpoint of a statistically significant increase in patients experiencing over a 50% reduction in urine leakage compared to baseline, as seen in the active treatment group versus the sham control group after 12 months. The trial also did not meet several secondary endpoints. Despite no serious device-related adverse events, the company made significant workforce reductions and started to explore strategic options due to its business prospects following the SUI trial. InMode’s acquisition of Viveve Medical’s assets does not stand alone; it complements the company’s existing patent portfolio. Additionally, InMode had previously entered an exclusive licensing agreement with the University of California for a bladder denervation patent, further enhancing its expertise in the field. “Development of products for Women’s Wellness continues to be a strategic pillar of our long-term growth strategy. By investing in new patents and licensing rights, InMode is not only strengthening its intellectual property portfolio but is also reaffirming its commitment to commercializing innovative technologies. InMode protects its IP worldwide against any company that attempts to infringe its proprietary rights,” said Moshe Mizrahy, InMode CEO. InMode is known for its novel radiofrequency (RF) technology, which has enabled the development of various medical devices catering to plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. The company’s minimally-invasive RF technologies have been widely accepted in the medical community and have improved existing treatments while introducing new surgical procedures. You May Also Like

Israeli Medtech Company InMode Acquires IP Assets from Viveve to Strengthen Its Position in the Women’s Health Space

USA - English
Share this article
Share this article
YOKNEAM, Israel, July 25, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq:  INMD ) (" InMode "), a leading global provider of innovative medical technologies, is pleased to announce the completion of a significant intellectual property (IP) transaction in the women's health and wellness market. InMode has acquired all the intellectual property assets of Viveve Medical Inc. Viveve is a medical technology company focused on women's wellness and the treatment of female stress urinary incontinence (SUI). All of Viveve's worldwide patents will be transferred and registered under InMode Ltd. The acquisition of Viveve's patent portfolio, in addition to an exclusive licensing agreement previously signed with the University of California relating to a bladder denervation patent, coupled with InMode's existing robust patent portfolio, fortifies InMode as the global market leader in women's wellness products development. "Development of products for Women's Wellness continues to be a strategic pillar of our long-term growth strategy. By investing in new patents and licensing rights, InMode is not only strengthening its intellectual property portfolio but is also reaffirming its commitment to commercializing innovative technologies. InMode protects its IP worldwide against any company that attempts to infringe its proprietary rights," said Moshe Mizrahy, InMode CEO. About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit  www.inmodemd.com . Also from this source
Enter Your Email
By signing up you agree to receive content from us. Our newsletters contain tracking pixels to help us deliver unique content based on each subscriber's engagement and interests. For more information on how we will use your data to ensure we send you relevant content please visit our  PRN Consumer Newsletter Privacy Notice . You can withdraw your consent at any time in the footer of every email you'll receive.Mit Ihrer Anmeldung erklären Sie sich damit einverstanden, Inhalte von uns zu erhalten. Unsere Newsletter enthalten Zählpixel, die die Lieferung einzigartiger Inhalte in Bezug auf das Abonnement und die Interessen der einzelnen Abonnenten ermöglichen. Weitere Informationen über die Verwendung Ihrer Daten im Hinblick auf die Zusendung von relevanten Inhalten, finden Sie in unserer  PRN Consumer Newsletter Privacy Notice . Ihre Zustimmung können Sie jederzeit in der Fußzeile jeder erhaltenen E-Mail widerrufen.En vous inscrivant à la newsletter, vous consentez à la réception de contenus de notre part. Notre newsletter contient des pixels espions nous permettant la fourniture à chaque abonné, d’un contenu unique en lien avec ses souscriptions et intérêts. Pour de plus amples informations sur l’utilisation faite de vos données en vue de l’envoi des contenus concernés, nous vous invitons à consulter la politique de confidentialité disponible à partir du lien suivant  PRN Consumer Newsletter Privacy Notice . Vous pouvez à tout moment revenir sur votre consentement par le biais des informations situées au bas de chaque e-mail reçu.Регистрирайки се, Вие се съгласявате да получавате информационно съдържание от нас. Нашите бюлетини съдържат проследяващи пиксели, които ни помагат да предоставяме уникално съдържание въз основа на ангажираността и интересите на всеки абонат. За повече информация относно начина, по който ще използваме Вашите данни, за да гарантираме, че Ви изпращаме подходящо съдържание, моля, направете справка с нашето Уведомление за поверителност на потребителския бюлетин на  PRN . Можете да оттеглите съгласието си по всяко време в долния колонтитул на всеки от имейлите, които ще получите.

08:00 ET
InMode Expands Women's Health and Wellness Market Footprint through Acquisition of Viveve Patents

July 25, 2023
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, is pleased to announce the completion of a significant intellectual property (IP) transaction in the women’s health and wellness market. InMode has acquired all the intellectual property assets of Viveve Medical Inc. Viveve is a medical technology company focused on women’s wellness and the treatment of female stress urinary incontinence (SUI). All of Viveve’s worldwide patents will be transferred and registered under InMode Ltd. The acquisition of Viveve’s patent portfolio, in addition to an exclusive licensing agreement previously signed with the University of California relating to a bladder denervation patent, coupled with InMode’s existing robust patent portfolio, fortifies InMode as the global market leader in women’s wellness products development. “Development of products for Women’s Wellness continues to be a strategic pillar of our long-term growth strategy. By investing in new patents and licensing rights, InMode is not only strengthening its intellectual property portfolio but is also reaffirming its commitment to commercializing innovative technologies. InMode protects its IP worldwide against any company that attempts to infringe its proprietary rights,” said Moshe Mizrahy, InMode CEO. About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency (“RF”) technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically-accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit  www.inmodemd.com .

InMode Acquires Viveve Patents

Our purpose at Delight Aesthetics is to be your one stop shop for your skincare and healthcare needs. We use our expertise to treat your various skincare and healthcare conditions. We also provide laser hair removal for all skin types, targeted facials, chemical peels, microneedling, radiofrequency microneedling, hair restoration and injectables which include Botox, Fillers, Viveve for stress urinary incontinence and vaginal rejuvenation. Address: 6744 Old Mclean Village Drive, Suite 2, Mclean, 22101, Virginia, USAE-mail: aesthetics@delightmd. comPhone Number: (571) 200-0566Website URL: https://delightmdaesthetics. Our purpose at Delight Aesthetics is to be your one stop shop for your skincare and healthcare needs. We use our expertise to treat your various skincare and healthcare conditions. We also provide laser hair removal for all skin types, targeted facials, chemical peels, microneedling, radiofrequency microneedling, hair restoration and injectables which include Botox, Fillers, Viveve for stress urinary incontinence and vaginal rejuvenation. Our purpose at Delight Aesthetics is to be your one stop shop for your skincare and healthcare needs. We use our expertise to treat your various skincare and healthcare conditions. We also provide laser hair removal for all skin types, targeted facials, chemical peels, microneedling, radiofrequency microneedling, hair restoration and injectables which include Botox, Fillers, Viveve for stress urinary incontinence and vaginal rejuvenation.

Delight Medical And Aesthetics

New York, New York, UNITED STATES
NEW YORK, Jan.  23, 2023  (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of Schmitt Industries, Inc. Schmitt Industries, Inc.’s common stock was suspended on January 17, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of Viveve Medical, Inc. Viveve Medical, Inc.’s common stock was suspended on January 19, 2023, and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the Common Stock and Warrant expiring 4/7/2025 of American Virtual Cloud Technologies, Inc. American Virtual Cloud Technologies, Inc.’s securities were suspended on January 20, 2023, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delistings. The delistings become effective ten days after the Form 25 is filed. For news and additional information about the companies, including the basis for the delisting and whether the companies’ securities are trading on another venue, please review the companies’ public filings or contact the company directly. For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com. Nasdaq’s rules governing the delisting of securities can be found in the Nasdaq Rule 5800 Series, available on the Nasdaq Web site: https://listingcenter.nasdaq.com/rulebook/nasdaq/rules/nasdaq-5800-series . -NDAQO-

Delisting of Securities of Schmitt Industries, Inc.; Viveve Medical, Inc.; and American Virtual Cloud Technologies, Inc. from The Nasdaq Stock Market

GreenSky operates in the consumer finance marketplace. The company engages in the home improvement, retail, and healthcare industries offering buy now, pay later (BNPL) services. GreenSky serves individuals looking for short-term lending facilities. The company was founded in 2006 and is based in Atlanta, Georgia.

GreenSky

ATLANTA -- -- GreenSky , LLC , a subsidiary of GreenSky , Inc. , a leading financial technology company Powering Commerce at the Point of Sale ® , today announced it has signed a strategic sponsorship agreement with Viveve Medical , Inc. , Inc to enable Viveve Medical , Inc. physician customers to offer customized financing solutions so their patients can receive the non?surgical solutions they seek .

Viveve® Partners with GreenSky Patient Solutions® to Offer Customized Financing for Women’s Health and Wellness Patients

Paragon Meditech is a medical technology company that focuses on women's intimate health. The company provides medical equipment. It is based in Shanghai City, Shanghai.

Paragon Meditech

ENGLEWOOD , CO / ACCESSWIRE / September 3 , 2019 / Viveve Medical , Inc. , a medical technology company focused on women 's intimate health , today announced an exclusive partnership agreement with Paragon , a leading women 's health and medical technology distributor throughout mainland China , Hong Kong and Macau .

Viveve Signs Exclusive Distribution Partnership with Paragon Meditech in Hong Kong, China and Macau :: Viveve Medical, Inc. (VIVE)

Salient Medical Solutions offers a variety of products, including diagnostic equipment, surgical and medical aesthetic technologies for dermatology, ophthalmology, otolaryngology, gynecology, phlebology and urology.

Salient Medical Solutions

ENGLEWOOD , CO / ACCESSWIRE / August 22 , 2019 / Viveve Medical , Inc. , a medical technology company focused on women 's intimate health , today announced an exclusive distribution agreement with Salient Medical Solutions , a leading distributor of innovative world-class medical devices and technologies in Canada .

Company Expands North America Commercial Capabilities.
Viveve Signs Exclusive Distribution Partnership in Canada with Salient Medical Solutions :: Viveve Medical, Inc. (VIVE)

Melon provides products and distribution services to companies that mainly service healthy people aiming to maintain or improve their health and beauty. The company's wide product range consists of products in the fields of aesthetics, anti-aging, cosmetology, wellness, and healthcare. Its product range includes treatment devices, instruments, supplies, and cosmetics. It was founded in 2008 and is based in Tampere, Finland.

Melon

Novelskin specializes in the distribution of products for medical aesthetics. It is based in  Paris, France.

Novelskin

Loan

Viveve, (NASDAQ: VIVE) is a women's health company focused on the commercialization of a revolutionary, non-surgical, non-ablative medical device that remodels collagen and restores vaginal tissue.

Wells Fargo Success Story

Professional Services

Platform Overview

Compare M2 Group Holdings vs Viveve Medical

Customers evaluate the quality of M2 Group Holdings's products using the following success metrics.